Trends and Innovations in Recombinant Protein Production

Recombinant protein production is evolving rapidly. What are the latest trends and innovations in recombinant protein production driving this field forward? This article delves into advanced expression systems, automation and engineering showcasing innovations shaping the future of protein production.

In addition to these technological innovations, the growing availability of specialized service providers has become a critical factor in recombinant protein production. Rodon Biologics offer extensive expertise in optimizing protein expression workflows across multiple platforms, including bacterial, mammalian and yeast systems. By combining deep knowledge of host strain selection, vector design, and process development with scalable production capabilities, we streamline the journey from gene to functional protein.

Rodon Biologics supports projects through expression optimization, process development, scale-up, and manufacturing, enabling the supply of high-quality proteins for research, reagents, therapeutics, and industrial applications. Working with Rodon allows researchers and companies to access expertise, technologies, workflows, and production without the need to invest heavily in internal infrastructure and accelerating timelines.

Key Takeaways

• Advances in expression systems, greatly enhance the yield and quality and range of recombinant proteins that can be produced at appropriate scale and cost, catering to diverse research, therapeutic, and industrial needs.
• Cell-free protein synthesis (CFPS) offers rapid production and the ability to incorporate modified amino acids, revolutionizing protein production without reliance on living cells.
• Innovations in automation and high-throughput screening simplify recombinant protein production, allowing for rapid identification, development, and optimization of the systems used for their expression and culture.

Expression Systems

Image 1 - An illustration characterising various expression systems

Advanced expression systems revolutionize recombinant protein expression by significantly enhancing yield and functionality. These systems have been meticulously designed to produce complex and functional proteins, providing researchers with robust tools for their scientific endeavors.

Bacterial Cells

Bacterial systems, primarily Escherichia coli, remain one of the most widely used platforms for recombinant protein production due to their rapid growth, well-characterized genetics, and cost-effectiveness. Recent innovations have expanded the utility of bacterial expression systems to overcome traditional limitations, such as improper protein folding, inclusion body formation, and limited post-translational modifications. Modern strategies include engineering strains with enhanced chaperone networks and redox environments that promote correct folding of complex proteins, as well as codon optimization and tunable promoters for precise control of expression levels.

Advances in secretion systems and cell-surface display allow for easier downstream purification and functional screening, while high-throughput screening and automated fermentation technologies accelerate the identification of high-yield clones. Synthetic biology tools, including CRISPR-based genome editing and modular plasmid systems, enable rapid pathway engineering and multi-gene expression, supporting the production of enzymes, metabolic products, and multi-subunit proteins. Additionally, bacterial systems are increasingly being combined with cell-free protein synthesis (CFPS), where bacterial extracts provide a scalable, flexible platform for rapid in vitro protein production. These innovations collectively maintain bacterial expression as a fast, scalable, and cost-efficient choice for research, industrial, and therapeutic protein applications.

Beyond E. coli, a variety of other bacterial systems are being increasingly explored for recombinant protein production, each offering unique advantages depending on the protein type and application. These include Bacillus subtilis, Lactococcus lactis, Pseudomonas spp., and Corynebacterium glutamicum.

Bacillus subtilis: Known for its strong secretion capabilities, B. subtilis allows direct export of proteins into the culture medium, simplifying purification. Recent innovations include genome-reduced strains that minimize protease activity and synthetic biology approaches to optimize promoter systems, secretion pathways, and codon usage for higher yields.

Lactococcus lactis: Widely used in food biotechnology and increasingly for therapeutics, L. lactis is a GRAS (Generally Recognized As Safe) organism that can secrete proteins efficiently. Engineering efforts focus on optimizing expression cassettes, secretion signals, and metabolic pathways to enhance yield and stability, particularly for oral vaccines and biologics.

Pseudomonas spp. Certain strains, like Pseudomonas fluorescens, are gaining attention for producing proteins that are difficult to express in E. coli due to toxicity or solubility issues. Innovations include engineered strains with improved folding and secretion, combined with tunable promoters for controlled expression.

Corynebacterium glutamicum: Traditionally used in amino acid production, C. glutamicum is now being adapted for recombinant protein expression. Its low protease activity, ability to secrete proteins, and amenability to metabolic engineering make it suitable for industrial-scale enzyme or therapeutic protein production.

These alternative bacterial systems complement E. coli by offering enhanced secretion, reduced proteolysis, and improved handling of complex or toxic proteins, expanding the versatility of bacterial platforms for research, industrial, and therapeutic applications.

Mammalian Cells

Mammalian expression systems are widely regarded for their ability to produce proteins with native folding, post-translational modifications and functional activity. These systems are particularly valuable for producing antibodies, complex proteins and proteins suitable for functional assays. Transient mammalian expression systems can yield gram-per-liter quantities of protein, making them a powerful tool for large-scale production. However, the culture conditions for mammalian cells in a host system are more demanding, requiring specific laboratory environments free from pathogenic microorganisms and equipped with essential culturing equipment.

Recent innovations in mammalian cell line development for protein expression have significantly improved efficiency and scalability. Precision gene editing tools like CRISPR-Cas9 and prime editing allow for targeted, stable integration of transgenes, while optimized expression vectors, including carefully designed regulatory elements and leader sequences, maximize transcription and translation efficiency. Transposon-based systems, such as piggyBac, Tol2, and Leap-In, complement these advances by enabling stable, high-copy integration of transgenes into transcriptionally active genomic regions. They support co-expression of multiple genes, which is essential for complex biologics like bispecific antibodies, and maintain high clonal stability over long-term culture, reducing the need for extensive screening.

Automation and high-throughput screening platforms accelerate the identification of high-producing clones, and advances in chemically defined media and feeding strategies ensure robust growth and consistent protein yields at scale. These innovations collectively create a more predictable, reproducible, and cost-effective framework for therapeutic protein production.

Yeast Cells

Yeast systems, particularly Saccharomyces cerevisiae and Pichia pastoris (Komagataella phaffii), have seen major innovations for recombinant protein production, making them a competitive alternative to mammalian cells for certain applications. Modern advances focus on improving protein yield, post-translational modifications, and scalability while retaining the inherent advantages of yeast: fast growth, low-cost media, and ease of genetic manipulation.

Key innovations include the development of engineered strains with enhanced secretion pathways and glycosylation capabilities that more closely mimic mammalian proteins. Synthetic biology approaches allow for the precise tuning of promoters, codon optimization, and multi-gene pathway integration to boost expression of complex proteins. High-throughput screening and automated fermentation platforms accelerate the identification of high-producing clones. Additionally, CRISPR/Cas-based genome editing has been adapted for yeast to enable precise, stable genomic integration and pathway engineering, improving both protein yield and consistency. Combined with optimized bioreactor designs and fed-batch strategies, these innovations have made yeast a highly versatile system for producing enzymes, vaccines, therapeutic proteins, and industrial biologics efficiently at scale.

Insect Cells

Insect cell systems, primarily based on Spodoptera frugiperda (Sf9, Sf21) and Trichoplusia ni (High Five) cells, have also seen significant innovations for recombinant protein expression, especially for complex eukaryotic proteins that require post-translational modifications. Insect cells are widely used with baculovirus expression vector systems (BEVS), which have been enhanced through modern molecular and synthetic biology approaches.

Key innovations include engineered baculovirus vectors with optimized promoters and multi-gene cassettes to improve protein yield and co-expression of subunits, which is critical for producing multi-protein complexes and virus-like particles (VLPs). Advances in glycoengineering have enabled insect cells to perform more human-like N-glycosylation, improving therapeutic relevance of recombinant proteins. CRISPR/Cas and other genome editing tools are being adapted for insect cell lines to enhance growth characteristics, protein processing, and secretion pathways. Coupled with high-density suspension cultures, optimized media formulations, and automated high-throughput screening platforms, these innovations have made insect cells a scalable, cost-effective, and versatile system for vaccines, biologics, and complex proteins that are challenging to produce in yeast or mammalian cells.

Cell-Free Protein Synthesis

Image 2 - Cell-free protein synthesis process

Cell-free protein synthesis (CFPS) is indeed a transformative technology that complements traditional cell-based expression systems like mammalian, yeast, and insect cells. Unlike conventional methods, CFPS does not rely on living cells; instead, it uses cell extracts containing the transcriptional and translational machinery necessary to produce proteins in vitro. This allows for highly controlled reaction conditions, rapid protein synthesis, and straightforward scalability, making CFPS ideal for applications requiring speed and flexibility. Researchers can produce proteins in hours rather than days, quickly test variants, and optimize expression without the time-consuming steps of cell culture, selection, and scale-up.

Another major advantage of CFPS is its ability to incorporate non-natural or chemically modified amino acids into proteins, which is often difficult in cell-based systems. This capability enables the production of proteins with enhanced stability, novel functionalities, or targeted modifications, expanding opportunities for drug development, enzyme engineering, and biomolecular studies. Additionally, CFPS facilitates the production of proteins that are toxic or otherwise challenging to express in living cells, including complex multi-subunit proteins, membrane proteins, and virus-like particles. Together, these attributes make CFPS a highly versatile and complementary approach to existing mammalian, yeast, and insect cell platforms, particularly for rapid prototyping, high-throughput screening, and specialized therapeutic protein production.

Scalability has historically been one of the main challenges for cell-free protein synthesis (CFPS) compared to conventional cell-based systems, but recent innovations are rapidly closing this gap. Traditional CFPS reactions were limited to small volumes (microliters to milliliters), mainly for research and high-throughput screening. However, advances in extract preparation, energy regeneration systems, and reactor design now allow CFPS to be scaled up to liter and even tens-of-liter production volumes, making it feasible for industrial applications. Continuous-exchange and perfusion-based CFPS setups maintain reagent supply and remove inhibitory byproducts, enabling extended reaction times and higher protein yields.

Moreover, CFPS is inherently modular and flexible, which simplifies scaling compared to living cells. Because there are no growth requirements, reactions can be run in parallel or in larger reactors without concerns about nutrient depletion, cell viability, or oxygen transfer limitations. This makes CFPS particularly attractive for rapid, on-demand production of therapeutic proteins, vaccine candidates, or enzymes, where fast response times and batch-to-batch consistency are critical. While large-scale mammalian or insect cell cultures may take weeks to establish, CFPS can produce equivalent amounts of protein in hours to days, offering a unique advantage in scenarios requiring speed and flexibility at scale.

Automation and High-Throughput Screening

Image 3 - An AI Generated Laboratory

Automation and high-throughput screening (HTS) are now central pillars of modern recombinant protein production, transforming the speed, precision, and scale of development pipelines. By integrating robotics, liquid-handling platforms, and advanced analytics, automation enables the rapid testing of thousands of protein variants or cell line clones in parallel. This not only accelerates the identification of high-yield, high-quality producers but also reduces variability and human error, ensuring more reproducible and consistent results. The streamlined workflows - from sample preparation and mixing to incubation and analysis- make protein production more efficient, cost-effective, and scalable.

High-throughput screening further amplifies these advantages by enabling systematic, parallelized testing. Microtiter plate–based assays and high-capacity readers allow the simultaneous evaluation of thousands of conditions, generating vast experimental datasets within a short timeframe. This is particularly critical for biotechnology and drug development, where identifying optimal protein variants, therapeutic targets, or biomarkers requires both speed and precision. When combined, automation and HTS provide a powerful toolkit for accelerating discovery, optimizing production processes, and ultimately advancing the development of new therapeutic and industrial proteins.

Engineering Difficult-to-Express Proteins

Some proteins in particular such as transmembrane proteins, multi-subunit complexes, and non-natural proteins present significant challenges including low expression, poor solubility, aggregation, misfolding, and in some cases, cellular toxicity. Overcoming these issues requires tailored, protein-specific strategies that combine molecular engineering with optimized expression platforms. Techniques such as codon optimization, gene truncation, protein fusion tags, and the co-expression of molecular chaperones can promote correct folding and increase solubility. Cultivation conditions, such as temperature, pH, and ionic strength, are also finely tuned to reduce stress on the host and enhance protein stability.

Transmembrane proteins are a prime example of Difficult to Express Proteins (DETPs) as their hydrophobic domains often reduce solubility and lead to aggregation. To address this, researchers employ detergents, lipid nanodiscs, or amphipols to mimic the membrane environment, alongside engineered host strains that provide suitable lipid compositions or folding assistance. For multi-subunit protein complexes, the challenge lies in ensuring correct stoichiometry and assembly, since many subunits are unstable outside of their native partners. Tailored strategies, such as co-expression of all subunits within the same host, optimization of subunit ratios, and use of scaffold proteins, help to stabilize folding and promote proper assembly. By leveraging protein engineering, appropriate expression hosts and vectors, and optimized production workflows, researchers are increasingly able to generate stable, functional DTEPs - expanding the frontiers of structural biology, drug discovery, and therapeutic protein development.